Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.

Chaoui D, Hacini M, Fitoussi O, Karlin L, Arkam Y, Jourdan E, Orfeuvre H, Voillat L, Sanhes L, Leprêtre S, Liu KL, Barry M, Tempescul A, Dilhuydy MS, Chaib A, Slama B, Labourey JL, Benbrahim O, Dreyfus B, Mahé B, Maynadié M, Delmer A, Benkanoun C, Boissard F, Gandon S, Veerabudun K, Choquet S; on behalf of the PERLE investigators .

Leuk Lymphoma. 2019 Jan 9:1-5. doi: 10.1080/10428194.2018.1533130. [Epub ahead of print] No abstract available.

PMID:
30624147
2.

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.

Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorvaux V, Bouadallah K, Amorin S, Garidi R, Voillat L, Joly B, Celigny PS, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB; Lymphoma Study Association.

Haematologica. 2019 Jan;104(1):138-146. doi: 10.3324/haematol.2018.191429. Epub 2018 Aug 31.

3.

Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.

Chaoui D, Choquet S, Sanhes L, Mahé B, Hacini M, Fitoussi O, Arkam Y, Orfeuvre H, Dilhuydy MS, Barry M, Jourdan E, Dreyfus B, Tempescul A, Leprêtre S, Bardet A, Leconte P, Maynadié M, Delmer A.

Leuk Lymphoma. 2017 Jun;58(6):1366-1375. doi: 10.1080/10428194.2016.1243673. Epub 2017 Feb 9.

PMID:
28271952
4.

Long-term benefit of intracardiac delivery of autologous granulocyte-colony-stimulating factor-mobilized blood CD34+ cells containing cardiac progenitors on regional heart structure and function after myocardial infarct.

Pasquet S, Sovalat H, Hénon P, Bischoff N, Arkam Y, Ojeda-Uribe M, Bouar Rl, Rimelen V, Brink I, Dallemand R, Monassier JP.

Cytotherapy. 2009;11(8):1002-15. doi: 10.3109/14653240903164963.

PMID:
19929464
5.

Role of the CD34+ 38- cells in posttransplant hematopoietic recovery.

Hénon P, Sovalat H, Bourderont D, Ojeda-Uribe M, Arkam Y, Wunder E, Raidot JP, Husseini F, Audhuy B.

Stem Cells. 1998;16 Suppl 1:113-22.

6.

Primordial role of CD34+ 38- cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation.

Hénon P, Sovalat H, Becker M, Arkam Y, Ojeda-Uribe M, Raidot JP, Husseini F, Wunder E, Bourderont D, Audhuy B.

Br J Haematol. 1998 Nov;103(2):568-81. Erratum in: Br J Haematol 1999 Jul;106(1):264. Bouderont D [corrected to Bourderont D].

PMID:
9827938

Supplemental Content

Support Center